Hot or Not, Stock Market Edition: 04/16/2026

Happy Thursday. Here are the stock stories we're following today:

• Hot: Pharmaceutical giant Takeda Pharmaceutical (TAK) looks poised to outperform; Government tech contractor Leidos Holdings (LDOS) is quietly setting up for a strong move.
• Not: biotech heavyweight Summit Therapeutics (SMMT) is showing its true colors; UWM Holdings (UWMC) is stuck in a tough spot with multiple headwinds

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: Is government tech contractor Leidos Holdings (LDOS) is quietly setting up for a strong move? Let’s take a peep. First, Leidos just closed its $2.4B acquisition of Entrust Solutions, instantly adding 3,100+ specialists and pushing the company deeper into energy and critical infrastructure. That’s a strategic shift into one of the most in-demand areas of the market right now. Second, the stock is still trading well below its recent trend, sitting around $152 while its 50-day and 200-day averages are up near $171 and $179. That disconnect tells you something: the market hasn’t fully priced in the deal yet. That’s where opportunity tends to live. Third, the fundamentals are backing it up. Leidos holds a Zen Rating of B (Buy) putting it in the top 20% of stocks we track overall, with standout scores in Value and strong marks across Financials, Safety, and Industry positioning.The bottom line? This is the kind of setup you want: a real catalyst, strong underlying fundamentals, and a stock that hasn’t caught up yet.  

🥶 NOT: Mortgage lender UWM Holdings (UWMC) isn’t just drifting. It’s stuck in a tough spot with multiple pressures working against it. Let’s start with the price action. The stock just slipped below its short-term trend and is now sitting more than 11% under its 50-day average. That’s a steady loss of momentum, and it tells you buyers aren’t stepping in. Then there’s the bigger problem: the business itself is fighting the environment. Mortgage demand is still constrained by elevated rates, refinancing activity is weak, and margins across the industry are under pressure. That’s not something management can fix overnight. It’s a structural headwind. Despite recent gains of 30% in the past 3 months, the stock is still down a hefty 20% on the year, and the underlying data isn’t helping. UWMC only earns a Zen Rating of C (Hold), with an F in Sentiment and D in Momentum. Basically, the market doesn’t trust the story and the trend is pointing down. Yes, Growth scores well; but in this case, it looks more like a spike than something durable. The verdict? Avoid (or at best, Hold). This is the kind of stock that can look “cheap” all the way down. Until rates ease and sentiment actually turns, you’re fighting both the chart and the macro—and that’s not a position you want to be in.

🔥 HOT: Pharmaceutical giant Takeda Pharmaceutical (TAK) is quietly building momentum, and this setup has breakout written all over it. Takeda is starting to get attention as a defensive play in a shaky global environment. With geopolitical risk rising, capital tends to rotate into stable, cash-generating pharma names — and Takeda fits that profile perfectly. But here’s the big one: TAK carries a Zen Rating of A (Strong Buy), putting it in the top 5% of all stocks we track. It’s not just one factor doing the work either — Growth, Momentum, Safety, and Value are all pulling in the same direction, with strong Component Grades (see them all here). The bottom line? This is the kind of name institutions hide in when markets get choppy—but with enough underlying strength to break higher if conditions improve. Quiet strength like this doesn’t stay quiet for long.

🥶 NOT:  Biotech heavyweight Summit Therapeutics (SMMT) is starting to crack — and the weakness isn’t random. Yes, analysts are talking up its massive market potential. But the stock isn’t trading on the dream — it’s trading on reality. And right now, the fundamentals aren’t backing it up. First, Summit sits near the bottom of its peer group, ranking 427 out of 459 biotech stocks (F-rated industry). That’s a red flag — because in biotech, relative strength matters. If the story were truly compelling, you’d expect it to outperform peers … not lag almost all of them. Second, the stock just fell to a Zen Rating of F or Strong Sell, putting it in the lowest tier of all stocks we track. The breakdown of the Component Grades is ugly: F in Sentiment, plus D grades in Financials, Growth, and Safety. Translation: weak balance sheet, questionable growth durability, and investors aren’t buying the story. The verdict? Even after a 36% run, this looks more like a speculative biotech bounce than a sustainable uptrend. Until the fundamentals catch up to the hype, the downside risk is real.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.